It’s All About the Culture . . . and Committing the Resources to Protect It and Yourself

January 5, 2015
Pharmaceutical Compliance Monitor

Types : Bylined Articles

The global reach of the U.S. Foreign Corrupt Practices Act and the anti-corruption regimes of other countries is ever expanding. Enforcement and regulatory agencies around the world are increasing global cooperation and communication and the business practices of companies – not only their own but also their “partners” (suppliers, distributors, agents, etc.) – come increasingly under the microscope and are often viewed and judged in hindsight. In turn, the consequences of violating the anti-corruption and anti-bribery laws are becoming more draconian. Whether it is the Chairman, the CEO or the accounts payable clerk, presumably none want that FBI knock on the door, or the fines, incarcerations, expenses, diversion from business or the damage to reputations. Earlier this year, the then head of the Criminal Division of the Department of Justice stated in an address to the Global Anti-corruption Compliance Congress.

Visit pharmacompliancemonitor.com for full article.